TPS was counted as the estimated percentage (0–100%) of tumor cells with partial or complete membranous PD-L1 immunostaining, and 26 (24.3%) patients exhibited a TPS of 1–49% and 81 (75.7%) patients displayed a TPS of 50–100% (Table 1). The gene discussed is CD274; the disease is neoplasm.